NASDAQ: AVXL

NASDAQ: AVXL

Press Releases

Read Anavex press releases covering company milestones, clinical trial updates, regulatory developments, and other corporate announcements.

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

January 13, 2026

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

January 8, 2026

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

January 6, 2026

Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

December 18, 2025

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

December 12, 2025

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 26, 2025

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

November 25, 2025

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

November 19, 2025

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

November 18, 2025

Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer’s Disease

November 14, 2025

Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group

October 29, 2025

Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’

October 10, 2025

Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program

October 2, 2025

Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

October 2, 2025

Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial

September 30, 2025

Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial

September 9, 2025

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

September 2, 2025

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine

August 26, 2025

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease

August 20, 2025

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

August 12, 2025

Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025

August 5, 2025

Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

July 31, 2025

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 14, 2025

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 13, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 6, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

May 1, 2025

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

April 30, 2025

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

April 23, 2025

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

April 21, 2025

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

April 5, 2025

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

February 24, 2025

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

February 12, 2025

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

February 5, 2025

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

January 27, 2025

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

January 15, 2025

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

January 13, 2025

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

December 23, 2024

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

December 23, 2024

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

December 16, 2024

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

December 9, 2024

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

December 2, 2024

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

November 26, 2024

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

November 25, 2024

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

October 31, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

October 17, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

September 3, 2024

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

August 6, 2024

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

August 1, 2024

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

July 30, 2024

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer’s Association Conference

July 28, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 20, 2024

Anavex Life Sciences Announces Expansion of Leadership Team

May 22, 2024

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 14, 2024

Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update

May 9, 2024

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

May 2, 2024

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

April 11, 2024

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 25, 2024

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

March 18, 2024

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

February 26, 2024

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

February 7, 2024